OOIR: Observatory of International Research

Papers

(The H4-Index of Dermatology and Therapy is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Canadian Expert Consensus on the Use of Halobetasol Propionate/Tazarotene Lotion for Plaque Psoriasis	123
Correction: Trifarotene Reduces Risk for Atrophic Acne Scars: Results from A Phase 4 Controlled Study	108
Publisher Correction to: Real-World Effectiveness of Dupilumab in Adult and Adolescent Patients with Atopic Dermatitis: 2-Year Interim Data from the PROSE Registry	92
Hair Shaft Abnormalities as a Dermoscopic Feature of Mycosis Fungoides: Pilot Results	71
Modulation of the Gut Microbiome to Enhance Immunotherapy Response in Metastatic Melanoma Patients: A Clinical Review	67
Adverse-Event Reports in Over-the-Counter Topical Acne Drug Products Containing Benzoyl Peroxide from a Specific Pharmaceutical Company in the USA	57
Sexual Dysfunction in Chronic Urticaria: A Systematic Review	55
Prurigo Nodularis: A Review of IL-31RA Blockade and Other Potential Treatments	50
Application of Comfort Therapy under eCASH Concept in Acute and Chronic Wound Treatment	50
Emerging Systemic Treatments for Atopic Dermatitis	48
Commentary on a Clinical Trial of Spesolimab, a Humanized Anti-interleukin-36 Receptor Monoclonal Antibody, in Generalized Pustular Psoriasis	47
Long-Term Efficacy and Safety of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: Updated Systematic Literature Review and Network Meta-analysis	44
Successful Treatment of Pityriasis Rubra Pilaris with Risankizumab in Children	41
Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials	39
The Impact of Step Therapy on Individuals with Psoriatic Disease in the USA: Patient and Provider Perspectives	39
Effectiveness of Tildrakizumab 200 mg in Moderate-to-Severe Plaque Psoriasis: A Multicenter Real-World Study Analyzing Patient Outcomes by Weight, PASI, BMI, and Previous Therapies	39
Determining Severity Strata for Three Atopic Dermatitis Patient-Reported Outcome Questionnaires: Defining Severity Score Ranges for the Worst Pruritus Numerical Rating Scale and the Atopic Dermatitis	38
Recognition and Management of Hereditary Angioedema: Best Practices for Dermatologists	37
Clinical and Disease Burden of Patients with Generalized Pustular Psoriasis: A Review of Real-World Evidence	37
Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) Study	37
Postinflammatory Papule: A Tentative New Designation for Acne Vulgaris	33
Effectiveness and Safety of Guselkumab for the Treatment of Psoriasis in Real-World Settings at 52 weeks: A Retrospective, Observational, Multicenter Study from China	30
Successful Treatment of Severe Pemphigus Vulgaris with Reduced Side Effects Using a Novel IVIg Preparation	30
Real-World Clinical, Psychosocial, and Economic Burden of Atopic Dermatitis: Results From the ESSENTIAL AD Multicountry Study	30
Efficacy of Upadacitinib and Dupilumab on Achieving Stringent and Composite Skin and Itch Outcomes: an Indirect Comparison of Adults with Moderate-to-Severe Atopic Dermatitis	28

Profound Sexual Dysfunction Among Patients with Hidradenitis Suppurativa: A Cross-sectional Study	28
Lichen Planopilaris Responsive to a Novel Phytoactive Botanical Treatment: A Case Series	27
Chlormethine Gel for Treatment of Patients with Mycosis Fungoides: Best Practices and Guidance to Clinicians	27
Maintenance and Concomitant Therapy Use with Chlormethine Gel Among Patients with Stage IA/IB Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma (MF-CTCL): A Real-World Evidence Study	27